Who are Ticagrelor standard tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clopidogrel only, aspirin + clopidogrel + celecoxib, prasugrel/bivalirudin, Clopidogrel active metabolite, Clopidogrel reloading, Clopidogrel, cilostazol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-standard-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ticagrelor standard tablets — Competitive Intelligence Brief

Ticagrelor standard tablets (Ticagrelor standard tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist (antiplatelet agent). Area: Cardiovascular.

phase 3 P2Y12 receptor antagonist (antiplatelet agent) P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ticagrelor standard tablets (Ticagrelor standard tablets) — Azienda Ospedaliero Universitaria di Sassari. Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ticagrelor standard tablets TARGET	Ticagrelor standard tablets	Azienda Ospedaliero Universitaria di Sassari	phase 3	P2Y12 receptor antagonist (antiplatelet agent)	P2Y12 receptor
Clopidogrel only	Clopidogrel only	Seung-Jung Park	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
aspirin + clopidogrel + celecoxib	aspirin + clopidogrel + celecoxib	Seoul National University Hospital	marketed	Antiplatelet agent combination with NSAID	COX-1, P2Y12 receptor, COX-2
prasugrel/bivalirudin	prasugrel/bivalirudin	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	marketed	Antiplatelet agent + Direct thrombin inhibitor combination	P2Y12 receptor (prasugrel); Thrombin (bivalirudin)
Clopidogrel active metabolite	Clopidogrel active metabolite	University of Florida	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Clopidogrel reloading	Clopidogrel reloading	University of Pecs	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist (antiplatelet agent) class)

Azienda Ospedaliero Universitaria di Sassari · 2 drugs in this class
Sheba Medical Center · 1 drug in this class
Sheffield Teaching Hospitals NHS Foundation Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticagrelor standard tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-standard-tablets. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab